Does an isolated serum GFAP IgM result diagnose autoimmune GFAP astrocytopathy or active astrocyte injury?

At age 83, an isolated serum GFAP-IgM result requires especially cautious interpretation and should not independently determine a neuroinflammatory diagnosis or treatment.

Diagnostic and clinical evidence

• Autoimmune GFAP astrocytopathy is associated with GFAPα-IgG, with the most diagnostically informative finding being CSF GFAP-IgG in a compatible acute/subacute inflammatory CNS syndrome. Interpretation also requires supportive MRI and inflammatory CSF findings.
• Serum-only antibody findings have limited specificity. In a Mayo Clinic cohort with paired samples from 49 patients with GFAP-IgG-associated disease, CSF was positive in 45/49 (92%), versus serum in 22/49 (45%).
• An isolated serum IgM result is not a validated diagnostic signature of GFAP astrocytopathy. Low-level serum-only reactivity may occur in controls and diverse neurologic or systemic conditions.

Mechanistic and biomarker interpretation

• Anti-GFAP IgM measures an immune response; it is not the same as measurement of free GFAP protein.
• Free GFAP in serum or CSF is a biomarker related to astrocyte injury, whereas GFAP autoantibodies principally serve as markers of an immune-associated inflammatory syndrome. Free-GFAP concentrations also require context because blood–brain-barrier transport and clearance can affect circulating levels.
• There is no credible validation that isolated serum GFAP-IgM independently tracks active astrocyte injury, relapse, MRI activity, or CSF inflammation.

Practical implications

• A lone serum GFAP-IgM result warrants analytical verification and clinical correlation, not an inference of active injury or treatment solely on that basis.
• If the clinical presentation raises concern for GFAP astrocytopathy, paired CSF/serum evaluation with GFAPα cell-based assay and tissue-based immunofluorescence is more informative.

Bottom line

• An isolated serum GFAP-IgM result is neither diagnostic of autoimmune GFAP astrocytopathy nor proof of active astrocyte injury.